Whole Blood Platelet Aggregometry and Platelet Function Testing

被引:92
作者
McGlasson, David L. [1 ]
Fritsma, George A. [2 ]
机构
[1] Wilford Hall USAF Med Ctr, Lackland AFB, TX 78236 USA
[2] Pathol Univ Alabama Birmingham, Birmingham, AL USA
关键词
Agonist; impedance-based whole blood aggregometry; lumiaggregometry; von Willebrand disease; platelet plasma membrane defects; platelet metabolic pathway defects; platelet secretion defects; aspirin-like disorder; storage pool disorder; antiplatelet therapy; aspirin resistance; thienopyridine resistance; LIGHT TRANSMISSION AGGREGOMETRY; STORAGE POOL DEFICIENCY; IMPEDANCE AGGREGOMETRY; ASPIRIN RESISTANCE; MYELOPROLIFERATIVE DISORDERS; ANTIPLATELET THERAPY; AGGREGATION; RECEPTOR; RESPONSIVENESS; REACTIVITY;
D O I
10.1055/s-0029-1220325
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Platelet aggregometry has been the reference method employed to detect, diagnose, and monitor qualitative platelet disorders since the early 1960s. Lumiaggregometry and impedance-based whole blood lumiaggregometry have advantages over light transmittance aggregometry in that they provide for enhanced specimen management and increase the test sensitivity to impairment of platelet granule secretion. Whole blood lumiaggregometry detects and identifies congenital and acquired platelet plasma membrane receptor defects, metabolic pathway secretion disorders, and storage pool deficiency. Whole blood lumiaggregometry is also being applied to antiplatelet therapy monitoring and identifies aspirin and thienopyridine resistance. There is growing interest in using impedance-based whole blood lumiaggregometry for near-patient whole blood platelet analysis and antiplatelet therapy monitoring. This article will also discuss other whole blood testing processes for assessing platelet function, particularly as applied to assessing the effect of antiplatelet medication.
引用
收藏
页码:168 / 180
页数:13
相关论文
共 92 条
[1]   High clopidogrel loading dose during coronary stenting:: effects on drug response and interindividual variability [J].
Angiolillo, DJ ;
Fernández-Ortiz, A ;
Bernardo, E ;
Ramírez, C ;
Sabaté, M ;
Bañuelos, C ;
Hernández-Antolín, R ;
Escaned, J ;
Moreno, R ;
Alfonso, F ;
Macaya, C .
EUROPEAN HEART JOURNAL, 2004, 25 (21) :1903-1910
[2]  
[Anonymous], 2008, H58A CLSI
[3]  
[Anonymous], HEMATOLOGY CLIN PRIN
[4]   Abnormalities of platelet aggregation in chronic myeloproliferative disorders [J].
Avrarn, S ;
Lupu, A ;
Angelescu, S ;
Olteanu, N ;
Mut-Popescu, D .
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2001, 5 (01) :79-87
[5]   Cardiac bypass haemostasis: Putting blood through the mill [J].
Bevan, DH .
BRITISH JOURNAL OF HAEMATOLOGY, 1999, 104 (02) :208-219
[6]  
BLACKWELL GJ, 1978, BRIT J PHARMACOL, V64, pP436
[7]  
BORN GVR, 1962, J PHYSIOL-LONDON, V162, pP67
[8]  
BORN GVR, 1963, J PHYSIOL-LONDON, V168, P178, DOI 10.1113/jphysiol.1963.sp007185
[9]  
BRACE LD, 2007, HEMATOLOGY CLIN PRIN, P654
[10]   Value of platelet reactivity in predicting response to treatment and clinical outcome in patients undergoing primary coronary intervention - Insights into the STRATEGY study [J].
Campo, Gianluca ;
Valgimigli, Marco ;
Gemmati, Donato ;
Percoco, Gianfranco ;
Tognazzo, Silvia ;
Cicchitelli, Giordano ;
Catozzi, Linda ;
Malagutti, Patrizia ;
Anselmi, Maurizio ;
Vassanelli, Corrado ;
Scapoli, Gianluigi ;
Ferrari, Roberto .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 48 (11) :2178-2185